• 1
    National Cancer Institute. Clinical Alert. Bethesda, Md: National Cancer Institute; 1988.
  • 2
    Burstein HJ, Harris JR, Morrow M. Malignant tumors of the breast. In: DeVitaVT, LawrenceTS, RosenbergSA, eds. Cancer Principles and Practice of Oncology. Philadelphia, Pa: Lippincott Williams Wilkins; 2008: 1606-1654.
  • 3
    Keime-Guibert F, Napolitano M, Delattre J-Y. Neurological complications of radiotherapy and chemotherapy. J Neurol. 1998; 245: 695-708.
  • 4
    Hortobagyi GN, Bodey GP, Buzdar AU, et al. Evaluation of high dose versus standard dose FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized trial. J Clin Oncol. 1987; 5: 354-364.
  • 5
    Yadav BS, Sharma SC. 5-fluorouracil associated encephalopathy: case report. Indian J Pharmacol. 2005; 37: 129-131.
  • 6
    Takimoto CH, Lu ZH, Zhang R, et al. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res. 1996; 2: 477-481.
  • 7
    Diamandidou E, Buzdar AU, Smith TL, et al. Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: The University of Texas M. D. Anderson cancer Center experience. J Clin Oncol. 1996; 14: 2722-2730.
  • 8
    Choi SM, Lee SH, Yang YS et al. 5-fluorouracil-induced leukoencephalopathy in patients with breast cancer. J Korean Med Sci. 2001; 16: 328-334.
  • 9
    Greenwald ES: Organic mental changes with fluorouracil (letter). J Am Med Assoc. 1976; 235: 248-249.
  • 10
    Royatta M, Raine CS. Taxol-induced neuropathy: chronic effect of local injection. J Neurocytol. 1986; 15: 483-496.
  • 11
    Guchelaar HJ, Ten Napel CHH, de Vries EGE, et al. Clinical, toxicological and pharmaceurical aspects of the antineoplastic drug taxol: a review. Clin Oncol. 1994; 6: 40-48.
  • 12
    Perry JR, Warner E. Transient encephalopathy after paclitaxel (Taxol) infusion. Neurology. 1996; 46: 1596-1599.
  • 13
    Ziske CG, Schottker B, Gorschluter M, et al. Acute transient encephalopathy after paclitaxel infusion: report of three cases. Ann Oncol. 2002; 13: 629-631.
  • 14
    Yavas O, Boruban C, Eren O, et al. Acute reversible life-threatening encephalopathy following conventional doses of paclitaxel infusion. The Internet Journal of Oncology. 2006; 3( 2).
  • 15
    Wefel JS, Lenzi R, Theriault RL, et al. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer. 2004; 100: 2292-2299.
  • 16
    Jenkins V, Shilling V, Deutsch G, et al. A 3-year prosepctive study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer. 2006; 94: 828-834.
  • 17
    Schagen SB, Muller MJ, Boogerd W, et al. Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. J Natl Cancer Inst. 2006; 98: 1742-1745.
  • 18
    Hurria A, Rosen C, Hudis C, et al. Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study. Am Geriatr Soc. 2006; 54: 925-931.
  • 19
    Bender CM, Sereika SM, Berga SL, et al. Cognitive impairment associated with adjuvant therapy in breast cancer. Psychooncology. 2006; 15: 422-430.
  • 20
    Hermelink K, Untch M, Lux MP, et al. Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer. 2007; 109: 1905-1913.
  • 21
    Quesnel C, Savard J, Ivers H. Cognitive impairments associated with breast cancer treatments: results from a longitudinal study. Breast Cancer Res Treat. 2008; 116: 113-123.
  • 22
    Stewart A, Collins B, Mackenzie J, et al. The cognitive effects of adjuvant chemotherapy in early stage breast cancer: a prospective study. Psychooncology. 2008; 17: 122-130.
  • 23
    Wefel JS, Lenzi R, Theriault R, et al. ‘Chemobrain’ in breast carcinoma? A prologue. Cancer. 2004; 101: 466-475.
  • 24
    Ahles TA, Saykin AJ, McDonald BC, et al. Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat. 2008; 110: 143-152.
  • 25
    Buzdar AU, Singletary SE, Theriault RL, et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol. 1999; 17: 3412-3417.
  • 26
    Ingraham LJ, Aiken CB. An empirical approach to determining criteria for abnormality in test batteries with multiple measures. Neuropsychology. 1996; 10: 120-124.
  • 27
    Chelune GJ, Naugle RI, Luders H, et al. Individual change after epilepsy surgery: practice effects and base-rate information. Neuropsychology. 1993; 7: 41-52.
  • 28
    Jacobsen NS, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consul Clin Psych. 1991; 59: 12-19.
  • 29
    Ouimet LA, Stewart A, Collins B, et al. Measuring neuropsychological change following breast cancer treatment: an analysis of statistical models. J Clin Exp Neuropsychol. 2009; 31: 73-89.
  • 30
    Dikmen SS, Heaton RK, Grant I, et al. Test-retest reliability and practice effects of Expanded Halstead-Reitan Neuropsychological Test Battery. J Int Neuropsychol Soc. 1999; 5: 346-356
  • 31
    McSweeny AJ, Naugle RI, Chelune GJ, et al. “T scores for change”: an illustration of a regression approach to depicting change in clinical neuropsychology. The Clin Neuropsychol. 2003; 7: 300-312.
  • 32
    Benedict RHB, Zgaljardic DJ. Practice effects during repeated administrations of memory tests with and without alternate forms. J Clin Exp Neuropsychol. 1998; 20: 339-352.
  • 33
    Wilson BA, Watson PC, Baddeley AD, et al. Improvement or simply practice? The effects of twenty repeated assessments on people with and without brain injury. J Int Neuropsychol Soc. 2000; 6: 469-479.
  • 34
    Temkin NR, Heaton RK, Grant I, et al. Detecting significant change in neuropsychological test performance: A comparison of four models. J Int Neuropsychol Soc. 1999; 5: 357-369.
  • 35
    Okeda R, Karakama T, Kimura S, et al. Neuropathologic study of chronic neurotoxicity of 5-fluorouracil and its masked compounds in dogs. Acta Neuropathologica. 1984; 63: 334-343.
  • 36
    Akiba T, Okeda R, Tajima T. Metabolites of 5-fluorouracil, alpha-beta-alanine and fluoroacetic acid, directly injure myelinated fibers in tissue culture. Acta Neuropathologica. 1996; 92: 8-13.
  • 37
    Winocur G, Vardy J, Binns MA, et al. The effects of the anti-cancer drugs, methotrexate and 5-fluorouracil, on cognitive function in mice. Pharmacol Biochem Behav. 2006; 85: 66-75.
  • 38
    Han R, Yang YM, Dietrich J, Luebke A, et al. Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. J Biol. 2008; 7:article 12.
  • 39
    Gandal MJ, Ehrlichman RS, Rudnick ND, et al. A novel elctrophysiological model of chemotherapy-induced cognitive impairments in mice. Neuroscience. 2008; 157: 95-104.
  • 40
    Dietrich J, Han R, Yang Y, et al. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol. 2006; 5:article 22.
  • 41
    Li CQ, Liu D, Huang L, et al. Cytosine arabinoside treatment impairs the remote spatial memory function and induces dendritic retraction in the anterior cingulated cortex of rats. Brain Res Bull. 2008; 77: 237-240.
  • 42
    Madhyastha S, Somayaji SN, Rao MS, et al. Hippocampal brain amines in methotrexate-induced learning and memory deficit. Can J Physiol Pharmacol. 2002; 80: 1076-1084.
  • 43
    Crandall J, Sakai Y, Zhang J, et al. 13-cis-retinoic acid suppresses hippocampal cell division and hippocampal-dependent learning in mice. PNAS. 2004; 101: 5111-5116.
  • 44
    Wechsler D. Wechsler Adult Intelligence Scale—Revised. San Antonio, Tex: The Psychological Corporation; 1981.
  • 45
    Reitan RM. Trail Making Test Manual for Administration and Scoring. Tucson, Ariz: Reitan Neuropsychology Laboratory; 1992.
  • 46
    Levine A, Miller E, Becker J, et al. Normative data for determining significance of test-retest differences on eight common neuropsychological instruments. The Clin Neuropsychol. 2004; 18: 373-384.
  • 47
    Brandt J. The Hopkins verbal learning test: development of a new memory test with six equivalent forms. The Clin Neuropsychol. 1991; 5: 125-142.
  • 48
    Benedict RHB, Schretlen D, Groninger L, et al. Hopkins verbal learning test-revised: normative data and analysis of inter-form and test-retest reliability. The Clin Neuropsychol. 1998; 12: 43-55.
  • 49
    Benton AL, Hamsher K. Multilingual Aphasia Examination. Iowa City: AJA Associates; 1983.
  • 50
    Ruff RM, Light RH, Parker SB. Benton controlled oral word association test: reliability and updated norms. Arch Clin Neuropsychol. 1996; 11: 329-338.
  • 51
    Beck AT, Steer RA. Beck Depression Inventory manual. San Antonio, Tex: The Psychological Corporation; 1987.
  • 52
    Spielberger CD, Gorsuch RL, Lushene R, et al. The State-Trait Anxiety Inventory. Palo Alto, Calif: Consulting Psychologists Press; 1983.
  • 53
    Brady MJ, Cella DF, Mo F, et al. Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument. J Clin Oncol. 1997; 15: 974-986.
  • 54
    Mehlsen M, Pedersen AD, Jensen AD, et al. No indications of cognitive side-effects in a prospective study of breast cancer patients receiving adjuvant chemotherapy. Psychooncology. 2009; 18: 248-257.
  • 55
    Shilling V, Jenkins V, Morris R, et al. The effects of adjuvant chemotherapy on cognition in women with breast cancer—preliminary results of an observational longitudinal study. The Breast. 2005; 14: 142-150.
  • 56
    Benedict RHB, Zgaljardic DJ. Practice effects during repeated administration of memory tests with and without alternate forms. JCEN. 1998; 20: 339-352.
  • 57
    Stern Y. What is cognitive reserve? Theory and research application of the reserve concept. JINS. 2002; 8: 448-460.